Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma

We conducted research on CDK4/6 inhibitors (CDK4/6i) simultaneously in the preclinical and clinical spaces to gain a deeper understanding of how senescence influences tumor growth in humans. We coordinated a first-in-kind phase II clinical trial of the CDK4/6i abemaciclib for patients with progressi...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical cancer research Vol. 30; no. 4; pp. 703 - OF16
Main Authors:	Gleason, Caroline E, Dickson, Mark A, Klein Dooley, Mary E, Antonescu, Cristina R, Gularte-Mérida, Rodrigo, Benitez, Marimar, Delgado, Juliana I, Kataru, Raghu P, Tan, Mark Wei Yi, Bradic, Martina, Adamson, Travis E, Seier, Kenneth, Richards, Allison L, Palafox, Marta, Chan, Eric, D'Angelo, Sandra P, Gounder, Mrinal M, Keohan, Mary Louise, Kelly, Ciara M, Chi, Ping, Movva, Sujana, Landa, Jonathan, Crago, Aimee M, Donoghue, Mark T A, Qin, Li-Xuan, Serra, Violetta, Turkekul, Mesruh, Barlas, Afsar, Firester, Daniel M, Manova-Todorova, Katia, Mehrara, Babak J, Kovatcheva, Marta, Tan, Nguan Soon, Singer, Samuel, Tap, William D, Koff, Andrew
Format:	Journal Article
Language:	English
Published:	United States 16-02-2024
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	We conducted research on CDK4/6 inhibitors (CDK4/6i) simultaneously in the preclinical and clinical spaces to gain a deeper understanding of how senescence influences tumor growth in humans. We coordinated a first-in-kind phase II clinical trial of the CDK4/6i abemaciclib for patients with progressive dedifferentiated liposarcoma (DDLS) with cellular studies interrogating the molecular basis of geroconversion. Thirty patients with progressing DDLS enrolled and were treated with 200 mg of abemaciclib twice daily. The median progression-free survival was 33 weeks at the time of the data lock, with 23 of 30 progression-free at 12 weeks (76.7%, two-sided 95% CI, 57.7%-90.1%). No new safety signals were identified. Concurrent preclinical work in liposarcoma cell lines identified ANGPTL4 as a necessary late regulator of geroconversion, the pathway from reversible cell-cycle exit to a stably arrested inflammation-provoking senescent cell. Using this insight, we were able to identify patients in which abemaciclib induced tumor cell senescence. Senescence correlated with increased leukocyte infiltration, primarily CD4-positive cells, within a month of therapy. However, those individuals with both senescence and increased TILs were also more likely to acquire resistance later in therapy. These suggest that combining senolytics with abemaciclib in a subset of patients may improve the duration of response. Abemaciclib was well tolerated and showed promising activity in DDLS. The discovery of ANGPTL4 as a late regulator of geroconversion helped to define how CDK4/6i-induced cellular senescence modulates the immune tumor microenvironment and contributes to both positive and negative clinical outcomes. See related commentary by Weiss et al., p. 649.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1078-0432 1557-3265
DOI:	10.1158/1078-0432.CCR-23-2378